DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: Previously, we demonstrated in a cross-sectional study that a consistent number of CML patients undergoing TKI treatment still harbored measurable residual PB CD26+LSCs, even when displaying a prolonged DMR and during a stable TFR.